SCHEMBL298699

SCHEMBL298699

O=C(NNC(=O)C1=CCCN(CC(=O)c2cccs2)C1)Nc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 6/20 0.47
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 3/20 0.47
GAA P10253 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
CCR2 P41597 1/20 0.44
KDM4E B2RXH2 2/20 0.43
POLB P06746 2/20 0.43
CASP1 P29466 1/20 0.42
HTR1A P08908 1/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298698 0.77 ALDH1A1 (0.41) LMNAHTTALDH1A1RAB9ANPC1
SCHEMBL287270 0.77 ALDH1A1 (0.47) LMNAHTTALDH1A1RAB9ANPC1
SCHEMBL1865063 0.76 RAB9A (0.75) LMNAHTTALDH1A1RAB9ANPC1
SCHEMBL287300 0.74 ALDH1A1 (0.48) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL297717 0.73 ALDH1A1 (0.41) HTTALDH1A1MEN1KMT2AMAPT
SCHEMBL297715 0.73 ALDH1A1 (0.41) HTTALDH1A1MEN1KMT2AMAPT
SCHEMBL297716 0.73 ALDH1A1 (0.41) HTTALDH1A1MEN1KMT2AMAPT
SCHEMBL297907 0.70 ALDH1A1 (0.45) LMNAHTTALDH1A1MEN1KMT2A
SCHEMBL1867069 0.65 RAB9A (0.73) ALDH1A1RAB9ANPC1MEN1KMT2A
SCHEMBL1858799 0.64 RAB9A (0.75) LMNAALDH1A1RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO claimed
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT LMNA 123/4885HTT 75/4885ALDH1A1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.